MORGAN STANLEY PLC/CALL/MEDTRONIC/110/0.1/20.12.24 Stock

Warrant

DE000MB8M3X1

Market Closed - Börse Stuttgart 14:37:26 2024-05-31 EDT
0.033 EUR +3.12% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/110/0.1/20.12.24
Current month-15.38%
1 month-15.38%
Date Price Change
24-05-31 0.033 +3.13%
24-05-30 0.032 -3.03%
24-05-29 0.033 -2.94%
24-05-28 0.034 +3.03%
24-05-27 0.033 -5.71%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 02:37 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB8M3X
ISINDE000MB8M3X1
Date issued 2023-07-12
Strike 110 $
Maturity 2024-12-20 (202 Days)
Parity 10 : 1
Emission price 0.3
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.36
Lowest since issue 0.025
Delta0.07x
Omega 13.40
Premium35.68x
Gearing200.01x
Moneyness 0.7397
Difference Strike 28.63 $
Difference Strike %+26.03%
Spread 0.005
Spread %12.50%
Theoretical value 0.0375
Implied Volatility 24.39 %
Total Loss Probability 95.28 %
Intrinsic value 0.000000
Present value 0.0375
Break even 110.41 €
Theta-0x
Vega0.01x
Rho0x

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
81.37 USD
Average target price
94.07 USD
Spread / Average Target
+15.61%
Consensus